NYC-based Biotechnology Company MimiVax Secures an Undisclosed Amount of Funding. Brain Tumour Investment Fund, a National Brain Tumour Society affiliate, participated in the round (NBTS).
The Sontag Innovation Fund, a subsidiary of the Sontag Foundation, the MEDA Angels, LLC, Varia Ventures and individual investors.
Read also – KY-based CSI Secures a Strategic Investment
The money will be used by the business to support the current phase 2b clinical investigation, carry out further work linked to registration, and get ready to commercialise SurVaxM for ndGBM.
MiniVax is a clinical-stage biotechnology business led by CEO Michael Ciesielski that focuses on immunotherapy research and the clinical translation of novel drugs for cancer treatment.
Read also – PA-based MedRisk Acquired Medata
It was established to research and market its lead candidate, SurVaxM, a proprietary immunotherapy that targets the cell-survival protein survivin. With subcutaneous delivery, SurVaxM inhibits tumour growth and stops illness recurrence by boosting the patient’s immune system.
About MimiVax
MimiVax is a privately held biotechnology firm at the clinical stage that specialises in the creation and marketing of targeted therapeutics and immunotherapeutic vaccines for the treatment of cancer.
Read also – CA-based Rainbow Secures $12M in Seed Funding
Their primary immunotherapeutic vaccine, SurVaxM, has finished a Phase 2a clinical trial in people who have just received a glioblastoma diagnosis.
